Can I Take Vitamin B6 with Wegovy?

The Short Answer: No Meaningful Interaction at Normal Doses

Vitamin B6 (pyridoxine) and semaglutide 2.4 mg operate through completely separate biological pathways. Semaglutide binds GLP-1 receptors in the pancreas, gut, and brain to suppress appetite and slow gastric emptying. Pyridoxine, once converted to its active form pyridoxal-5-phosphate (PLP), acts as a coenzyme in over 100 enzymatic reactions involving amino acid metabolism, neurotransmitter synthesis, and one-carbon metabolism. Neither drug modulates the other's receptor, enzyme system, or metabolic clearance pathway.

No interaction is listed in the FDA prescribing information for Wegovy, and no pharmacokinetic interaction study between semaglutide and pyridoxine has been published in the primary literature as of mid-2025. The absence of a shared metabolic route makes a pharmacokinetic interaction biologically implausible.

Why Pharmacokinetic Interactions Are Unlikely

Semaglutide is metabolized by proteolytic cleavage, not by cytochrome P450 enzymes [1]. Pyridoxine is converted hepatically to PLP via pyridoxal kinase and pyridox(am)ine phosphate oxidase, enzymes that have no documented interaction with GLP-1 receptor agonists [2]. There is no shared transporter, no shared enzyme family, and no shared receptor.

A pharmacodynamic conflict would require the two substances to push the same physiological variable in opposing directions. No such opposition exists here.

What the FDA Label Does and Does Not Say

The Wegovy prescribing label lists delayed gastric emptying as a mechanism-based effect that can reduce the rate (but not always the extent) of absorption of orally co-administered drugs [3]. For most small-molecule vitamins, including pyridoxine, this effect is pharmacologically trivial because B6 absorption occurs broadly across the jejunum and does not depend on a narrow absorption window [4].

Understanding Vitamin B6: Doses, Forms, and What "High Dose" Means

Vitamin B6 is sold in doses ranging from 2 mg (a standard multivitamin) to 500 mg (therapeutic formulations marketed for premenstrual syndrome or nausea). These are not equivalent from a safety standpoint.

The RDA and Typical Supplement Range

The National Institutes of Health Office of Dietary Supplements sets the adult RDA for B6 at 1.3 mg/day for adults aged 19 to 50 and 1.5 to 1.7 mg/day for those over 50 [2]. Standard multivitamins typically contain 2 to 10 mg per tablet, well within the range considered safe for long-term use.

The tolerable upper intake level (UL) established by the Institute of Medicine is 100 mg per day for adults [2]. This ceiling exists because human case series documented peripheral sensory neuropathy in patients taking 50 to 500 mg of pyridoxine daily for extended periods.

The Neuropathy Risk at High Doses

A 1983 case series by Schaumburg et al. (N=7) first characterized high-dose pyridoxine neuropathy, documenting sensory ataxia and distal limb paresthesias in patients consuming 2,000 mg per day for months [5]. Subsequent reports lowered the threshold of concern considerably. A 2017 systematic review in the Netherlands identified 24 confirmed cases, with the lowest dose causing neuropathy at approximately 50 mg per day taken chronically [6].

The mechanism is direct neurotoxicity to dorsal root ganglion neurons when PLP accumulates beyond the capacity of binding proteins. Symptoms are generally reversible after stopping supplementation, though recovery can take months at high exposures.

Wegovy does not modify this risk. The neuropathy is a property of excessive B6 alone.

Doses Sold for Nausea Management

B6 at 10 to 25 mg three times daily (30 to 75 mg/day total) is used in some clinical contexts for nausea, most notably in pregnancy-related nausea under the brand name Diclegis (doxylamine plus pyridoxine 10 mg) [7]. Patients on Wegovy sometimes seek B6 for GLP-1-associated nausea, which peaks in weeks 1 to 8 of dose escalation. Doses in the 10 to 25 mg per-dose range sit close to or below the threshold at which chronic neuropathy risk begins to appear in the literature, but patients taking these doses long-term should be aware of cumulative daily intake across all supplements.

Wegovy-Associated Nausea and the B6 Question

Nausea is the most common adverse event reported in the STEP-1 trial, occurring in 44.2% of the semaglutide group versus 16.1% of the placebo group [8]. This nausea is central and peripheral in origin: semaglutide slows gastric emptying and activates area postrema neurons in the brainstem. STEP-1 (N=1,961) showed 14.9% mean body weight loss at 68 weeks in the semaglutide 2.4 mg arm versus 2.4% in the placebo arm, underscoring why patients and clinicians accept some early GI side effects as part of the benefit-risk equation [8].

Does B6 Actually Help GLP-1-Related Nausea?

No randomized controlled trial has evaluated pyridoxine specifically for semaglutide-related nausea. The evidence that B6 reduces nausea in non-pregnant adults outside of the pregnancy context is limited. A 2014 Cochrane review on interventions for nausea and vomiting in early pregnancy found that vitamin B6 alone reduced nausea severity scores compared with placebo (RR 0.61, 95% CI 0.43 to 0.87), but this population and mechanism may not translate directly to GLP-1-induced nausea [7].

Using B6 at 10 to 25 mg per dose for a few weeks during Wegovy dose escalation carries low risk. The concern arises if a patient continues high doses for months or stacks multiple B6-containing products without tracking total daily intake.

Practical Nausea Strategies That Have Trial Evidence

The STEP-1 dose escalation protocol itself (four-week titration steps from 0.25 mg to 2.4 mg) is designed to minimize nausea [8]. Eating smaller meals, avoiding high-fat foods, and not lying down within three hours of eating have been recommended in the FDA-approved prescribing label as supportive measures [3]. B6 can be tried as an adjunct; just keep total daily intake below 100 mg and ideally below 50 mg for ongoing use.

Drug Interactions That Actually Matter: B6 Drug-Drug Context

Vitamin B6 does have clinically meaningful interactions with specific prescription drugs. Patients on Wegovy who are also taking any of the following should discuss B6 supplementation with their prescriber.

Isoniazid (INH) and Pyridoxine Depletion

Isoniazid, used to treat tuberculosis, inhibits pyridoxal kinase and causes functional B6 deficiency. The American Thoracic Society guidelines recommend supplementing with 25 to 50 mg of pyridoxine daily in patients receiving isoniazid who are at risk for neuropathy (diabetics, malnourished individuals, pregnant women, and patients with HIV) [9]. A patient on both Wegovy and INH should be taking supplemental B6, not avoiding it.

Hydralazine and Penicillamine

Hydralazine and penicillamine form hydrazones with pyridoxal, depleting functional B6. The clinical consequence is a peripheral neuropathy that mimics high-dose B6 neuropathy in presentation but is caused by deficiency rather than excess. Patients on these medications who are also on Wegovy may benefit from modest B6 supplementation (10 to 25 mg/day) to maintain adequate PLP levels [2].

Levodopa

High-dose B6 (above 5 to 10 mg per day) accelerates peripheral decarboxylation of levodopa, reducing the amount that crosses the blood-brain barrier and blunting its antiparkinsonian effect. This interaction is clinically irrelevant when levodopa is co-administered with a peripheral decarboxylase inhibitor (carbidopa), as is standard practice in most current formulations [2]. Patients on carbidopa-levodopa (Sinemet) who also take Wegovy and B6 do not need to restrict B6 for this reason.

Gastric Emptying Delay: Does Wegovy Affect B6 Absorption?

Semaglutide slows gastric emptying. This is the mechanism behind its satiety effect and also the basis for the label warning about oral drug co-administration. The question is whether this delay meaningfully reduces pyridoxine absorption.

Pyridoxine Absorption Physiology

Pyridoxine is absorbed via passive diffusion throughout the small intestine, with the highest absorption rates in the jejunum [4]. Because absorption does not depend on a tight anatomical window or a saturable transporter in the way that some drugs do (levothyroxine, for example), delayed gastric emptying is unlikely to cause a clinically meaningful reduction in total pyridoxine bioavailability. The supplement simply spends more time in the stomach before reaching the jejunum, but once there, absorption proceeds normally.

Drugs Where This Does Matter

In contrast, the FDA label for Wegovy specifically references the oral contraceptive and acetaminophen pharmacokinetic studies conducted during the semaglutide phase 2 program. For acetaminophen, semaglutide reduced the mean Cmax by approximately 22% and delayed Tmax, though total AUC was not significantly reduced [3]. For drugs with narrow therapeutic windows or Cmax-dependent efficacy, this matters. For pyridoxine, it does not.

Who Should Use Extra Caution

Most Wegovy patients taking a standard multivitamin or a dedicated B6 supplement at 2 to 25 mg per day have no reason for special concern. A few groups warrant closer attention.

The following framework can help clinicians and patients quickly stratify their individual risk when combining B6 with Wegovy:

Group 1: Standard multivitamin users (B6 2 to 10 mg/day) No action needed. Total intake falls far below the neuropathy threshold. No dose separation required.

Group 2: Dedicated B6 supplement users (10 to 50 mg/day) Track total daily B6 across all products. Acceptable for short-term nausea management (weeks to months). If use extends beyond three months at 50 mg/day, discuss with a clinician.

Group 3: High-dose B6 users (50 to 100 mg/day or above) This range approaches or exceeds the threshold identified in neuropathy case reports [6]. Seek a clinical review of whether this dose is medically indicated. Routine high-dose B6 without a documented deficiency or a specific drug-depletion scenario is difficult to justify.

Group 4: Patients on isoniazid, hydralazine, or penicillamine B6 supplementation is likely beneficial in this group, not harmful. Confirm dosing with the prescribing physician.

Group 5: Patients with pre-existing peripheral neuropathy Any new or worsening tingling, burning, or sensory loss in the hands or feet should prompt evaluation regardless of B6 dose, because semaglutide has its own rare neuropathy signal (acute ophthalmic nerve events have been reported, though a causal link remains unconfirmed) [10].

Monitoring and Lab Considerations

Routine measurement of serum pyridoxal-5-phosphate is not clinically indicated for patients on Wegovy taking standard supplement doses.

When to Check B6 Levels

Plasma PLP measurement becomes reasonable when a patient presents with new sensory neuropathy symptoms and is taking more than 50 mg of B6 daily, or when a drug-depletion interaction (isoniazid, hydralazine) is suspected. Reference ranges for plasma PLP are typically 20 to 125 nmol/L in most laboratory systems, though toxicity thresholds in case reports have been associated with levels exceeding 500 nmol/L.

Neuropathy Symptom Surveillance

Patients combining Wegovy with B6 above 50 mg/day should be counseled to report distal paresthesias, unsteady gait, or reduced hand coordination. These symptoms, if caused by B6 toxicity, typically begin in the feet and ascend symmetrically. Onset is usually subacute, developing over weeks to months of sustained high-dose exposure [5].

Practical Guidance: What to Tell Your Provider

Transparency matters. Tell your Wegovy prescriber about every supplement you take, including the dose and brand, because individual products vary considerably in their B6 content. A protein powder, a B-complex, a multivitamin, and a dedicated B6 tablet taken together can sum to a surprising daily total.

The Endocrine Society's 2015 clinical practice guideline on obesity pharmacotherapy states: "Patients should inform clinicians about all medications and dietary supplements being used, as some supplements may interact with weight-loss pharmacotherapy or independently affect metabolic parameters." [11] This principle applies directly here.

A patient who reports 200 mg of B6 per day, which is sold in some sports-nutrition products marketed for energy metabolism, should be counseled to reduce to 10 mg or less unless a specific clinical indication exists.

Summary Table: B6 Dose Categories and Risk With Wegovy

| Daily B6 Dose | Risk Category | Recommended Action | |---|---|---| | 1 to 10 mg (multivitamin) | Negligible | No change needed | | 10 to 50 mg (low supplement) | Low | Track cumulative sources; short-term fine | | 50 to 100 mg (moderate supplement) | Moderate | Clinical review if sustained over 3 months | | Above 100 mg (high dose) | Elevated neuropathy risk | Reduce dose; confirm medical indication | | 25 to 50 mg (INH co-administration) | Beneficial, not harmful | Continue per ATS guideline |